Baricitinib

Generic Name
Baricitinib
Brand Names
Olumiant
Drug Type
Small Molecule
Chemical Formula
C16H17N7O2S
CAS Number
1187594-09-7
Unique Ingredient Identifier
ISP4442I3Y
Background

Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses.
...

Indication

In the US and Europe, baricitinib is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF blockers. Baricitinib may be used as monotherapy or in combination with methotrexate or other DMARDs.
...

Associated Conditions
Alopecia Areata (AA), Coronavirus Disease 2019 (COVID‑19), Severe Atopic Dermatitis, Moderate Atopic dermatitis, Moderate, active Rheumatoid arthritis, Severe, active Rheumatoid arthritis
Associated Therapies
-
Clinical Trials
Related News

Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.

Phase 2
Conditions
Pharmacological Action
Interventions
Drug: Baricitinib
First Posted Date
2020-03-24
Last Posted Date
2020-04-22
Lead Sponsor
Hospital of Prato
Target Recruit Count
200
Registration Number
NCT04320277
Locations
🇮🇹

Fabrizio Cantini, Prato, Tuscany, Italy

JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult IIM

Phase 2
Completed
Conditions
Idiopathic Inflammatory Myopathies
Interventions
Drug: Baricitinib
First Posted Date
2019-12-23
Last Posted Date
2023-10-18
Lead Sponsor
University of Manchester
Target Recruit Count
15
Registration Number
NCT04208464
Locations
🇬🇧

King's College Hospital NHS Foundation Trust, London, United Kingdom

Baricitinib for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation

First Posted Date
2019-10-18
Last Posted Date
2023-05-10
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
26
Registration Number
NCT04131738
Locations
🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis

Phase 3
Active, not recruiting
Conditions
Uveitis
Interventions
Drug: Baricitinib
Drug: Adalimumab
First Posted Date
2019-09-12
Last Posted Date
2024-12-13
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
30
Registration Number
NCT04088409
Locations
🇫🇷

Hôpitaux Universitaires Paris Sud - Hôpital Bicêtre, Le Kremlin Bicetre, France

🇫🇷

Hôpital Universitaire Necker Enfants Malades, Paris, France

🇫🇷

Centre Hospitalier Universitaire de Poitiers, Poitiers Cedex, France

and more 17 locations

A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)

First Posted Date
2019-09-12
Last Posted Date
2024-12-04
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
58
Registration Number
NCT04088396
Locations
🇧🇷

Hospital de Clínicas Da Universidade Estadual de Campinas, Campinas, São Paulo, Brazil

🇫🇷

Centre Hospitalier Régional Universitaire de Nancy - Hôpitaux de Brabois, Vandoeuvre lès Nancy, Meurthe-et-Moselle, France

🇯🇵

Institute of Science Tokyo Hospital, Bunkyō, Tokyo, Japan

and more 64 locations

A Study of Baricitinib in Participants With Rheumatoid Arthritis

Phase 4
Recruiting
Conditions
Rheumatoid Arthritis
Interventions
Drug: Baricitinib
Drug: TNF Inhibitor
First Posted Date
2019-09-12
Last Posted Date
2024-12-09
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
1300
Registration Number
NCT04086745
Locations
🇺🇸

Arizona Research Clinic PLLC, Chandler, Arizona, United States

🇺🇸

Smart Cures Clinical Research, Anaheim, California, United States

🇺🇸

Wallace Rheumatic Study Center, Beverly Hills, California, United States

and more 116 locations

BAriCitinib Healing Effect in earLy pOlymyalgia Rheumatica

Phase 2
Completed
Conditions
Polymyalgia Rheumatic (PMR)
Interventions
Drug: Placebos
Drug: Baricitinib
First Posted Date
2019-07-19
Last Posted Date
2023-11-29
Lead Sponsor
University Hospital, Brest
Target Recruit Count
34
Registration Number
NCT04027101
Locations
🇫🇷

CHU Montpellier, Montpellier, France

🇫🇷

CH Le Mans, Le Mans, France

🇫🇷

CHU Strasbourg, Strasbourg, France

and more 5 locations

A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis

Phase 3
Active, not recruiting
Conditions
Atopic Dermatitis
Interventions
Drug: Placebo
Drug: Baricitinib
Drug: Topical corticosteroid
First Posted Date
2019-05-16
Last Posted Date
2024-12-20
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
516
Registration Number
NCT03952559
Locations
🇦🇺

Veracity Clinical Research, Woolloongabba, Queensland, Australia

🇧🇷

Faculdade de Medicina do ABC, Santo André, Sao Paulo, Brazil

🇨🇿

Fakultni Nemocnice v Motol, Praha, Praha 5, Czechia

and more 75 locations

Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions in Healthy Adult Male Subjects

Early Phase 1
Completed
Conditions
Allergic Contact Dermatitis
Interventions
Drug: Placebo
Drug: Baricitinib
First Posted Date
2019-05-10
Last Posted Date
2023-12-05
Lead Sponsor
Wright State Physicians
Target Recruit Count
23
Registration Number
NCT03945760
Locations
🇺🇸

Wright State Physicians, Fairborn, Ohio, United States

JAK Inhibitor Treatment in AGS

Phase 2
Completed
Conditions
Aicardi Goutieres Syndrome
Interventions
Drug: Baricitinib
First Posted Date
2019-04-19
Last Posted Date
2024-05-23
Lead Sponsor
Adeline Vanderver, MD
Target Recruit Count
54
Registration Number
NCT03921554
Locations
🇺🇸

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy